Scientists probe the root cause of a rare bone marrow disease
NCT ID NCT07607392
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at blood vessel cells from 30 people with primary myelofibrosis, a rare bone marrow disorder. Researchers wanted to see if these cells act like stem cells that could be the origin of the disease. By growing the cells in the lab, they aimed to understand how the disease develops.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help explain how primary myelofibrosis starts, potentially pointing toward new treatment targets.
- What could go wrong
- This is a small, completed observational study with only 30 participants. It does not test any treatment, so it may not lead directly to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Italy, 27100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action pill tame bone marrow tumors?
- Can a new pill shrink the spleen in myelofibrosis?
- Can a daily pill shrink the spleen in myelofibrosis?
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- Can a modified interferon rein in early myelofibrosis?
- Can a drug free myelofibrosis patients from frequent blood transfusions?